A 'break­through' PD-1? From Chi­na? FDA says why not for rare can­cer

5 years ago
China
FDA+

Brent Saun­ders piv­ots from Al­ler­gan sale to a $460M SPAC, mak­ing him an overnight play­er in one of the hottest ...

5 years ago
Deals

Pas­cal So­ri­ot says 2020 ap­proval still pos­si­ble for As­traZeneca's Covid-19 vac­cine as the world awaits the safe­ty ...

5 years ago
Coronavirus

As Chi­na's tech gi­ants catch on­to biotech, Baidu plots $2B start­up fo­cused on di­ag­no­sis, AI drug dis­cov­ery

5 years ago
Financing
China

Ora­sis Phar­ma­ceu­ti­cals snags $30M to see its pres­by­opia treat­ment through to PhI­II

5 years ago
Financing
R&D

Co­di­ak files for an IPO, again, this time shoot­ing for a nine-dig­it raise

5 years ago
Financing

News brief­ing: Take­da re­ports PhI­II fail­ure for Nin­laro in mul­ti­ple myelo­ma; As­traZeneca plots piv­ot to Nas­daq

5 years ago
News Briefing

Ex­clu­sive: Gink­go teams with un­known up­start in hunt for Covid-19 an­ti­body

5 years ago
Startups
Coronavirus

Phase III mi­graine flop sends a small-cap biotech play­er in­to a dead­ly tail­spin

5 years ago
R&D

An­i­mal da­ta in hand, Nes­san Berming­ham banks $91.5M for At­las-backed RNA edit­ing play

5 years ago
Financing

Trel­e­gy gets FDA thumbs-up for asth­ma, be­com­ing first triple-com­bo ther­a­py in the US

5 years ago
FDA+

FDA knocks back Sarep­ta in Duchenne gene ther­a­py race with Pfiz­er, but an­a­lysts urge cau­tion

5 years ago
R&D
FDA+

FL56+FL57= in­fi­nite pos­si­bil­i­ties? Flag­ship's hy­brid start­up takes ma­chine learn­ing in drug dis­cov­ery to the next ...

5 years ago
Startups
AI

Mi­NA Ther­a­peu­tics bags near­ly $30M Se­ries A to push ac­ti­vat­ing mR­NA tech through the clin­ic

5 years ago
Financing
Cell/Gene Tx

Re­cur­sion nabs $239M and an up to $1B part­ner­ship with Bay­er as AI race heats up

5 years ago
Financing
Deals

With pos­i­tive PhI­II da­ta, Mer­ck sets up a block­buster at­tempt to over­throw Pfiz­er's reign­ing Pre­vnar 13

5 years ago
R&D

$1.6 bil­lion liq­uid biop­sy play­er Grail files IPO, re­veal­ing 2021 com­mer­cial plans and a Mi­das-sized $65M pay pack­age ...

5 years ago
People
Financing

News brief­ing: Catal­ent, Mer­ck KGaA make big in­vest­ments in man­u­fac­tur­ing ops; J&J teams with Data­vant on da­ta ...

5 years ago
News Briefing

Long­time biotech vet An­drew Hirsch is tak­ing the top job at C4 — and he clear­ly has some big plans

5 years ago
People
R&D

On­coIm­mune pulls in $56M Se­ries B, hop­ing GvHD pro­gram can prove use­ful for Covid-19

5 years ago
R&D

Pay­ing down more debt, Take­da of­floads pre­scrip­tion drug port­fo­lio for $562 mil­lion

5 years ago
Deals

Mak­er of world's most ex­pen­sive pre­scrip­tion drug flash­es PhI­II da­ta for a po­ten­tial fourth prod­uct

5 years ago
R&D

Covid-19 roundup: Fau­ci re­it­er­ates Oc­to­ber vac­cine OK 'un­like­ly'; Pfiz­er and BioN­Tech re­serve 200M dos­es for EU

5 years ago
Coronavirus

Dab­bling in CD47, Pfiz­er in­fus­es $25M in­to a biotech play­er tout­ing pos­i­tive monother­a­py da­ta

5 years ago
Deals
R&D
First page Previous page 803804805806807808809 Next page Last page
A service from the Financial Times